DNAH1: A Potential Drug Target and Biomarker (G25981)

Target Name: DNAH1

NCBI ID: G25981

DNAH1

DNAH1: A Potential Drug Target and Biomarker

Introduction

DNAH1 (deoxyribonucleotide H1) is a protein that is expressed in various tissues and cells of the human body. It is a member of the DNA polymerase family 1 and is involved in the process of DNA replication and repair. DNAH1 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The Importance of DNAH1

DNAH1 plays a crucial role in maintaining the integrity of DNA replication and repair. It is an essential enzyme that helps ensure that the genetic information in DNA is accurately copied and that any errors or mutations are repaired. DNAH1 is also involved in the regulation of the DNA replication process, which is essential for cell growth and division.

DNAH1 has been implicated in various diseases

The role of DNAH1 in disease has been attributed to its involvement in DNA replication and repair. Several studies have shown that DNAH1 is often mutated or hyper-expressed in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, studies have shown that DNAH1 mutations are associated with an increased risk of cancer, including breast, ovarian, and prostate cancers. Additionally, DNAH1 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases.

Potential Drug Target

The potential drug target for DNAH1 is based on its involvement in DNA replication and repair. Drugs that target DNAH1 have been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to targeting DNAH1 is to use small molecules that inhibit the activity of DNAH1. These drugs have been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Another approach to targeting DNAH1 is to use antibodies that recognize and target DNAH1. These antibodies have been shown to be effective in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker

DNAH1 has also been identified as a potential biomarker for various diseases. The expression of DNAH1 is often increased in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Additionally, the activity of DNAH1 has been shown to be affected by various factors, including age, gender, and environmental factors. For example, studies have shown that the expression of DNAH1 is often increased in older individuals and that exposure to certain environmental factors, Such as radiation and chemicals, can also increase the expression of DNAH1.

Conclusion

In conclusion, DNAH1 is a protein that is involved in the process of DNA replication and repair. It has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential of drugs that target DNAH1 is based on their ability to inhibit its activity and their ability to recognize and target DNAH1. Further research is needed to fully understand the role of DNAH1 in disease and to develop effective treatments.

Protein Name: Dynein Axonemal Heavy Chain 1

Functions: Force generating protein of cilia required for sperm flagellum motility. Produces force towards the minus ends of microtubules. Dynein has ATPase activity; the force-producing power stroke is thought to occur on release of ADP. Required in spermatozoa for the formation of the inner dynein arms and biogenesis of the axoneme (PubMed:24360805)

The "DNAH1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNAH1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets